Exact Sciences Corporation (EXAS)

Market Cap	19.74B +94.8%
Revenue (ttm)	3.25B +17.7%
Net Income	-207.95M
EPS	-1.10
Shares Out	190.89M
PE Ratio	n/a
Forward PE	91.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,708,010
Open	103.30
Previous Close	103.29
Day's Range	103.20 - 103.50
52-Week Range	38.81 - 103.54
Beta	1.42
Analysts	Hold
Price Target	85.64 (-17.2%)
Earnings Date	Feb 13, 2026

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 7,200
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS
• Website: https://www.exactsciences.com

Financial Performance

In 2025, Exact Sciences's revenue was $3.25 billion, an increase of 17.69% compared to the previous year's $2.76 billion. Losses were -$207.95 million, -79.79% less than in 2024.

Analyst Summary

According to 18 analysts, the average rating for EXAS stock is "Hold." The 12-month stock price target is $85.64, which is a decrease of -17.20% from the latest price.

Price Target

$85.64

(-17.20% downside)

Analyst Consensus: Hold